Centessa Pharmaceuticals Files DEFA14A Proxy Materials
Ticker: CNTA · Form: DEFA14A · Filed: May 28, 2025 · CIK: 1847903
| Field | Detail |
|---|---|
| Company | Centessa Pharmaceuticals PLC (CNTA) |
| Form Type | DEFA14A |
| Filed Date | May 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, corporate-governance
TL;DR
Centessa Pharma filed proxy docs, no fee needed. Standard corporate housekeeping.
AI Summary
Centessa Pharmaceuticals plc filed a Definitive Additional Materials (DEFA14A) on May 28, 2025. This filing relates to their proxy statement and indicates no fee was required for this submission. The company is incorporated in X0 with its fiscal year ending on December 31.
Why It Matters
This filing is a routine regulatory submission for Centessa Pharmaceuticals, providing additional materials related to their proxy statement, which is crucial for shareholder voting and corporate governance.
Risk Assessment
Risk Level: low — This filing is a routine DEFA14A, indicating standard corporate disclosure rather than a significant event.
Key Players & Entities
- Centessa Pharmaceuticals plc (company) — Registrant
- 0001999371-25-006737 (filing_id) — Accession Number
- 20250528 (date) — Filing Date
FAQ
What type of filing is this?
This is a DEFA14A filing, specifically Definitive Additional Materials related to a proxy statement.
Who is the filer?
The filer is Centessa Pharmaceuticals plc.
When was this filing made?
The filing was made on May 28, 2025.
Was there a filing fee associated with this document?
No fee was required for this filing.
What is the company's fiscal year end?
Centessa Pharmaceuticals plc's fiscal year ends on December 31.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 28, 2025 regarding Centessa Pharmaceuticals plc (CNTA).